Benjamin P. Linas, MD

Associate Professor, Infectious Diseases

Associate Professor, Epidemiology

Benjamin Linas
Sections

Infectious Diseases

Biography

Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Education

Medicine, MD, New York University School of Medicine, 2000

Clinical Evaluation/Research, MPH, Harvard School of Public Health, 2006

Economics, BA, Yale University, 1995

Publications

Published on 7/27/2020

Kimmel SD, Walley AY, Linas BP, Kalesan B, Awtry E, Dobrilovic N, White L, LaRochelle M. Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug- and Non-Injection Drug-Associated Endocarditis. Clin Infect Dis. 2020 Jul 27; 71(3):480-487. PMID: 31598642.

Published on 7/2/2020

Muyindike WR, Fatch R, Cheng DM, Emenyonu NI, Ngabirano C, Adong J, Linas BP, Jacobson KR, Hahn JA. Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. PLoS One. 2020; 15(7):e0235261. PMID: 32614873.

Published on 6/27/2020

Assoumou SA, Nolen S, Hagan L, Wang J, Eftekhari Yazdi G, Thompson WW, Mayer KH, Puro J, Zhu L, Salomon JA, Linas BP. Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. Am J Med. 2020 Jun 27. PMID: 32603791.

Published on 4/14/2020

Zhu L, Menzies NA, Wang J, Linas BP, Goodreau SM, Salomon JA. Estimation and correction of bias in network simulations based on respondent-driven sampling data. Sci Rep. 2020 Apr 14; 10(1):6348. PMID: 32286412.

Published on 3/17/2020

Assoumou SA, Tasillo A, Vellozzi C, Eftekhari Yazdi G, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. Clin Infect Dis. 2020 Mar 17; 70(7):1388-1396. PMID: 31095676.

Published on 3/17/2020

Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis. 2020 Mar 17; 70(7):1397-1405. PMID: 31095683.

Published on 3/4/2020

Assoumou SA, Wang J, Nolen S, Eftekhari Yazdi G, Mayer KH, Puro J, Salomon JA, Linas BP. HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. J Gen Intern Med. 2020 May; 35(5):1477-1483. PMID: 32133577.

Published on 2/1/2020

Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020 Feb; 71(2):686-721. PMID: 31816111.

Published on 1/30/2020

Morgan JR, Wang J, Barocas JA, Jaeger JL, Durham NN, Babakhanlou-Chase H, Bharel M, Walley AY, Linas BP. Opioid overdose and inpatient care for substance use disorder care in Massachusetts. J Subst Abuse Treat. 2020 May; 112:42-48. PMID: 32199545.

Published on 1/30/2020

Linas BP. Time for a New Approach to Guidance for HIV and HCV Testing Among Persons Who Inject Drugs. J Infect Dis. 2020 Jan 30. PMID: 32002538.